Welcome to our dedicated page for AMGEN SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen director S. Omar Ishrak reported the acquisition of 121.4308 shares of Amgen common stock on 08/08/2025 via vested restricted stock units under the Amgen Inc. 2009 Director Incentive Program. The transaction is shown at a $0 price, reflecting issuance of shares upon vesting, and the Form 4 was signed on 08/09/2025.
The filing reports 6,241.9302 shares beneficially owned following the transaction, held directly. The reported shares include 291 Dividend Equivalents credited to vested but deferred RSUs and payable in shares under a dividend reinvestment arrangement. The document identifies the reporting person as a director of Amgen (AMGN).
On 08/08/2025 Amgen director Charles M. Holley reported the immediate vesting of restricted stock units (RSUs) granted under Amgen's Director Incentive Program. The vested RSUs were converted to common stock on a one-for-one basis and recorded as an acquisition (transaction code A) with a reported price of $0.
Following the reported transaction Holley beneficially owns 11,469.6259 shares directly and 1,260 shares indirectly through the Holley Family Trust. The filing also shows 1,294 Dividend Equivalents credited to vested but deferred RSUs, which are payable in shares one-for-one with cash for any fractional share amounts.
Michael V. Drake, a director of Amgen Inc. (AMGN), reported the vesting and conversion of Restricted Stock Units into 121.4308 shares on 08/08/2025. The vested RSUs convert one-for-one into common stock and were reported at a purchase price of $0, reflecting compensation rather than an open-market trade. After the transaction his direct beneficial ownership is reported as 4,699.0291 shares. The reported amount includes 227 Dividend Equivalents credited on vested-but-deferred RSUs that are paid in shares under the Director Incentive Program and the Amgen Inc. 2009 Equity Incentive Plan.